Cryogenx has secured £1.7 million in seed funding to advance its innovative solution for combating heatstroke and heat-related illnesses. Their flagship product, the CGX1, acts like a “defibrillator for heat,” offering rapid treatment without the need for ice or refrigeration. The portable device is designed for quick deployment, making it ideal for military, industrial, and emergency scenarios where high temperatures pose significant risks.
The investment, led by UKI2S and managed by Future Planet Capital, aims to support Cryogenx in scaling its operations and expanding its impact across both defense and civilian sectors. The company plans to use the funds to obtain FDA clearance, increase manufacturing capacity, and boost international sales. Additionally, Cryogenx is working on developing lighter, modular versions of its technology and exploring a subscription-based model for sustained revenue.
With projections indicating that 700 million people will face extreme heat by 2030, the urgency of addressing heat stress is clear. Heatstroke and related conditions not only threaten lives but also result in substantial economic losses, with productivity declines expected to reach $2.4 trillion annually. Cryogenx’s CGX1 offers a scalable solution at a critical time, targeting a global health and economic challenge exacerbated by climate change.
